Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis

• Status: Completed
• Trial end date: 2020-01-30
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the efficacy and safety of the administration of betalactam antibiotics in prolonged infusion compared to intermittent infusion in children with sepsis. Half of participants will receive piperacillin/tazobactam, imipenem or meropenem in continuous or extended infusion, while the other half will receive piperacillin/tazobactam, imipenem or meropenem in intermittent infusion.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Coordinación de Investigación en Salud, Mexico
• Collaborators: Hospital Infantil de Mexico Federico Gomez; Hospital Regional de Alta Especialidad del Bajio; Instituto Mexicano del Seguro Social
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; beta-Lactams; Imipenem; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins

Criteria

Inclusion Criteria:

• Patients diagnosed with sepsis, who have been evaluated by an infectious physician and are candidates to receive piperacillin/tazobactam, imipenem or meropenem as empiric treatment.

Exclusion Criteria:

• Patients with a history of allergy to one or more of the proposed antibiotics.

• Patients with chronic kidney disease or acute renal failure.

• Patients with acute liver failure of any cause.

• Patients in palliative or supportive care only.